Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

CE: Original Research: Primary Care Providers and Screening for Military Service and PTSD.

Mohler KM, Sankey-Deemer C.

Am J Nurs. 2017 Nov;117(11):22-28. doi: 10.1097/01.NAJ.0000526720.34516.4b.

PMID:
29035900
2.

Fully human CD19-specific chimeric antigen receptors for T-cell therapy.

Sommermeyer D, Hill T, Shamah SM, Salter AI, Chen Y, Mohler KM, Riddell SR.

Leukemia. 2017 Oct;31(10):2191-2199. doi: 10.1038/leu.2017.57. Epub 2017 Feb 16.

3.

Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeys.

Nickerson-Nutter C, Tchistiakova L, Seth NP, Kasaian M, Sibley B, Olland S, Zollner R, Brady WA, Mohler KM, Baum P, Wahl A, Herber D, Vugmeyster Y, Wensel D, Wolfman NM, Gill D, Collins M, Dunussi-Joannopoulos K.

Rheumatology (Oxford). 2011 Jun;50(6):1033-44. doi: 10.1093/rheumatology/keq423. Epub 2011 Jan 21.

4.

Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.

Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustian S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS.

Bioorg Med Chem Lett. 2003 Aug 18;13(16):2799-803.

PMID:
12873518
5.

Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.

Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS.

Bioorg Med Chem Lett. 2003 Apr 17;13(8):1487-90.

PMID:
12668018
6.

Immune function in patients with rheumatoid arthritis treated with etanercept.

Moreland LW, Bucy RP, Weinblatt ME, Mohler KM, Spencer-Green GT, Chatham WW.

Clin Immunol. 2002 Apr;103(1):13-21.

PMID:
11987981
7.

Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.

Levin JI, Chen JM, Du MT, Nelson FC, Killar LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS.

Bioorg Med Chem Lett. 2002 Apr 22;12(8):1199-202.

PMID:
11934588
8.

The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.

Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotnicki JS.

Bioorg Med Chem Lett. 2001 Nov 19;11(22):2975-8.

PMID:
11677139
9.

The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.

Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, Sung A, Sharr M, Roth C, Jin G, Cowling R, Mohler KM, Black RA, March CJ, Skotnicki JS.

Bioorg Med Chem Lett. 2001 Aug 20;11(16):2189-92.

PMID:
11514167
10.

Use of targeted anticytokine treatments in heart failure.

Mohler KM, Murray KM, Mann DL, Francis G.

Circulation. 2000 Aug 29;102(9):E65. No abstract available.

PMID:
10961980
11.

Role of the type 1 TNF receptor in lung inflammation after inhalation of endotoxin or Pseudomonas aeruginosa.

Skerrett SJ, Martin TR, Chi EY, Peschon JJ, Mohler KM, Wilson CB.

Am J Physiol. 1999 May;276(5):L715-27. doi: 10.1152/ajplung.1999.276.5.L715.

PMID:
10330027
12.

Cytokine and cytotoxic pathways of NK cell rejection of class I-deficient bone marrow grafts: influence of mouse colony environment.

Bennett M, Taylor PA, Austin M, Baker MB, Schook LB, Rutherford M, Kumar V, Podack ER, Mohler KM, Levy RB, Blazar BR.

Int Immunol. 1998 Jun;10(6):785-90.

PMID:
9678759
13.

TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation.

Peschon JJ, Torrance DS, Stocking KL, Glaccum MB, Otten C, Willis CR, Charrier K, Morrissey PJ, Ware CB, Mohler KM.

J Immunol. 1998 Jan 15;160(2):943-52.

14.

Further evidence for a common mechanism for shedding of cell surface proteins.

Müllberg J, Rauch CT, Wolfson MF, Castner B, Fitzner JN, Otten-Evans C, Mohler KM, Cosman D, Black RA.

FEBS Lett. 1997 Jan 20;401(2-3):235-8.

15.

Relaxed specificity of matrix metalloproteinases (MMPS) and TIMP insensitivity of tumor necrosis factor-alpha (TNF-alpha) production suggest the major TNF-alpha converting enzyme is not an MMP.

Black RA, Durie FH, Otten-Evans C, Miller R, Slack JL, Lynch DH, Castner B, Mohler KM, Gerhart M, Johnson RS, Itoh Y, Okada Y, Nagase H.

Biochem Biophys Res Commun. 1996 Aug 14;225(2):400-5.

PMID:
8753775
16.

CD40/CD40 ligand interactions are required for T cell-dependent production of interleukin-12 by mouse macrophages.

Kennedy MK, Picha KS, Fanslow WC, Grabstein KH, Alderson MR, Clifford KN, Chin WA, Mohler KM.

Eur J Immunol. 1996 Feb;26(2):370-8.

PMID:
8617306
17.

Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome.

Eason JD, Pascual M, Wee S, Farrell M, Phelan J, Boskovic S, Blosch C, Mohler KM, Cosimi AB.

Transplantation. 1996 Jan 27;61(2):224-8.

PMID:
8600628
18.

A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor.

Müllberg J, Durie FH, Otten-Evans C, Alderson MR, Rose-John S, Cosman D, Black RA, Mohler KM.

J Immunol. 1995 Dec 1;155(11):5198-205.

PMID:
7594530
19.

A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes.

Crowe PD, Walter BN, Mohler KM, Otten-Evans C, Black RA, Ware CF.

J Exp Med. 1995 Mar 1;181(3):1205-10.

20.

Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing.

Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Alderson M, Kerwar SS, Torrance DS, Otten-Evans C, Greenstreet T, Weerawarna K, et al.

Nature. 1994 Jul 21;370(6486):218-20.

PMID:
8028669
21.

Induction of B cell costimulatory function by recombinant murine CD40 ligand.

Kennedy MK, Mohler KM, Shanebeck KD, Baum PR, Picha KS, Otten-Evans CA, Janeway CA Jr, Grabstein KH.

Eur J Immunol. 1994 Jan;24(1):116-23.

PMID:
7517359
22.

Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists.

Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB.

J Immunol. 1993 Aug 1;151(3):1548-61.

PMID:
8393046
23.

Identification of a distinct low-affinity receptor for human interleukin-4 on pre-B cells.

Fanslow WC, Spriggs MK, Rauch CT, Clifford KN, Macduff BM, Ziegler SF, Schooley KA, Mohler KM, March CJ, Armitage RJ.

Blood. 1993 Jun 1;81(11):2998-3005.

PMID:
8499634
25.

Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection.

Silva JS, Morrissey PJ, Grabstein KH, Mohler KM, Anderson D, Reed SG.

J Exp Med. 1992 Jan 1;175(1):169-74.

27.

Differential production of IL-2 and IL-4 mRNA in vivo after primary sensitization.

Mohler KM, Butler LD.

J Immunol. 1990 Sep 15;145(6):1734-9.

PMID:
2391417
28.

Interleukin 1-induced pathophysiology: induction of cytokines, development of histopathologic changes, and immunopharmacologic intervention.

Butler LD, Layman NK, Cain RL, Riedl PE, Mohler KM, Bobbitt JL, Belagajie R, Sharp J, Bendele AM.

Clin Immunol Immunopathol. 1989 Dec;53(3):400-21.

PMID:
2680192
29.

In vitro detection of lymphokines produced by in vivo activated lymphocytes.

Mohler KM, Butler LD.

J Immunol Methods. 1989 Jul 6;121(1):67-73.

PMID:
2787822
30.
32.

Suppression in class II MHC tolerance is mediated by Ia-specific lymphocytes that fail to mature into allodestructive effectors.

Streilein JW, Mohler KM.

Transplant Proc. 1989 Feb;21(1 Pt 1):236-7. No abstract available.

PMID:
2523129
33.

Interleukin-2 induced systemic toxicity: induction of mediators and immunopharmacologic intervention.

Butler LD, Mohler KM, Layman NK, Cain RL, Riedl PE, Puckett LD, Bendele AM.

Immunopharmacol Immunotoxicol. 1989;11(2-3):445-87.

PMID:
2695567
35.

Allo-I-J determinants participate in maintenance of neonatal H-2 tolerance.

Mohler KM, Strome PG, Streilein JW.

J Immunol. 1987 Jan 1;138(1):70-7. Erratum in: J Immunol 1987 Mar 15;138(6):2008.

PMID:
2946781
36.

Ability of neonatally induced tolerance of Ia antigens to overcome adoptive transfer of allo-Ia immunity and to erase its memory.

Streilein JW, Strome PG, Mohler KM, Wood PJ.

Transplantation. 1984 Jan;37(1):106-7. No abstract available.

PMID:
6364477

Supplemental Content

Loading ...
Support Center